The biotech IPO train keeps chugging, as Virios prices $30M public debut

Virios Therapeutics priced its public debut on Thursday, bringing home $30 million and contributing to this year’s record raise of nearly $15 billion. However, the Atlanta-based biotech raised less than its initial goal set in August, and much less than other IPOs we’ve seen this year, many of which featured upsized offerings. Virios’ 3 million shares came in at $10 apiece, the midpoint of a $9 to $11 range.